Abstract library

4 results for "Molina".
#466 HIF-1a Determines the Metastatic Potential of the GEP-NET Cell Line BON-1
Introduction: Intratumoral hypoxia is a hallmark of solid tumor formation and a negative predictor of patient survival. Adaptation to hypoxia is mainly achieved by the transcription factor HIF-1a, which is upregulated in a diverse range of human and experimental tumors and their metastases. HIF-1a target genes have been implicated in the induction of invasion and metastasis. However, HIF-1a’s tumor-supporting action depends on cell type and microenvironment and the precise role of HIF-1a for the pathogenesis of neuroendocrine tumors (NET) is largely unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Katja Freitag de Molina
#2075 Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Rosa Maria Antonijoan Arbós
#2973 Robustness of Radiomic Features in 68Ga-DOTATOC PET/CT: A Monocentric Experience for Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of malignancies with varied histology, localization and behaviour.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Virginia Liberini
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini